| Literature DB >> 10720509 |
W Borkowsky1, D Wara, T Fenton, J McNamara, M Kang, L Mofenson, E McFarland, C Cunningham, A M Duliege, D Francis, Y Bryson, S Burchett, S A Spector, L M Frenkel, S Starr, R Van Dyke, E Jimenez.
Abstract
Children of mothers infected with human immunodeficiency virus type 1 (HIV-1) were immunized at birth and at 1, 3, and 5 months with 1 of 3 doses of recombinant gp120 vaccines prepared from SF-2 or MN strains of HIV-1. A total of 126 children were not infected; 21 received adjuvant only. Vaccine recipients developed lymphoproliferative responses on >/=2 occasions, responding more often to homologous HIV-1 antigens than did adjuvant recipients (56% vs. 14%; P<.001). Responses were appreciated after 2 immunizations and were maintained for >84 weeks after the last immunization. An accelerated immunization schedule (birth, 2 weeks, 2 months, and 5 months) with the lowest dose of the SF-2 vaccine produced responses in all 11 vaccinees by 4 weeks. Responses to heterologous envelope antigens were also detected. Immune responses to vaccination are achievable at an age when some infection (perinatal or breast milk exposure related) may be prevented.Entities:
Mesh：
Substances：
Year: 2000 PMID： 10720509 DOI： 10.1086/315298
Source DB: PubMed Journal: J Infect Dis ISSN： 0022-1899 Impact factor: 5.226